Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Down 82.1% in April

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totaling 107,543 shares, a decline of 82.1% from the April 15th total of 599,897 shares. Based on an average trading volume of 19,736 shares, the days-to-cover ratio is presently 5.4 days. Currently, 29.5% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

JAGX has been the topic of several recent analyst reports. Wall Street Zen upgraded Jaguar Animal Health from a “strong sell” rating to a “sell” rating in a research note on Sunday. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Jaguar Animal Health has a consensus rating of “Hold” and a consensus target price of $2,100.00.

Jaguar Animal Health Stock Down 1.5%

Shares of JAGX traded down $0.05 during mid-day trading on Tuesday, reaching $3.25. The company’s stock had a trading volume of 29,585 shares, compared to its average volume of 96,923. The business has a fifty day moving average of $14.16 and a 200 day moving average of $31.06. The company has a market cap of $1.20 million, a price-to-earnings ratio of 0.00 and a beta of 0.01. Jaguar Animal Health has a 1 year low of $2.53 and a 1 year high of $283.85. The company has a quick ratio of 0.29, a current ratio of 0.50 and a debt-to-equity ratio of 4.08.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.